0.72
+0.011(+1.56%)
Currency In USD
| Previous Close | 0.7 |
| Open | 0.74 |
| Day High | 0.78 |
| Day Low | 0.7 |
| 52-Week High | 6.7 |
| 52-Week Low | 0.55 |
| Volume | 179,528 |
| Average Volume | 2.28M |
| Market Cap | 2.59M |
| PE | -0.08 |
| EPS | -8.48 |
| Moving Average 50 Days | 0.88 |
| Moving Average 200 Days | 1.84 |
| Change | 0.01 |
If you invested $1000 in ZyVersa Therapeutics, Inc. (ZVSA) since IPO date, it would be worth $0.21 as of April 25, 2025 at a share price of $0.715. Whereas If you bought $1000 worth of ZyVersa Therapeutics, Inc. (ZVSA) shares 2 years ago, it would be worth $1.27 as of April 25, 2025 at a share price of $0.715.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
GlobeNewswire Inc.
Yesterday at 11:57 AM GMT
WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseas
ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS)
GlobeNewswire Inc.
Apr 08, 2025 11:57 AM GMT
WESTON, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseas
ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study
GlobeNewswire Inc.
Mar 18, 2025 11:57 AM GMT
In obesity-associated cardiomyopathy (OAC), heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with congestive heart failure and sudden cardiac death pred